Improved Survival Through Early Versus Late Impella Support for Myocardial Infarction-Related Shock?: Mind Your Step!

Christiaan L Meuwese; Claartje L A Pladet; Adriaan O Kraaijeveld; Dirk W Donker

doi:10.1097/CCM.0000000000005256

Improved Survival Through Early Versus Late Impella Support for Myocardial Infarction-Related Shock? Mind Your Step!

Christiaan L Meuwese
, Claartje L A Pladet
, Adriaan O Kraaijeveld
, Dirk W Donker

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	e1276-e1277
Journal	Critical care medicine
Volume	49
Issue number	12
DOIs	https://doi.org/10.1097/CCM.0000000000005256
Publication status	Published - 1 Dec 2021

Access to Document

10.1097/CCM.0000000000005256

Cite this

@article{2b75c8eb937649848979ffaa675c35f4,

title = "Improved Survival Through Early Versus Late Impella Support for Myocardial Infarction-Related Shock?: Mind Your Step!",

author = "Meuwese, \{Christiaan L\} and Pladet, \{Claartje L A\} and Kraaijeveld, \{Adriaan O\} and Donker, \{Dirk W\}",

note = "Funding Information: Dr. Kraaijeveld{\textquoteright}s institution received funding from Xenios and Abiomed; he received funding from Abiomed. Dr. Donker received funding from Getinge Maquet and Fresenius Xenios Nova Lung. The remaining authors have disclosed that they do not have any potential conflicts of interest. ",

year = "2021",

month = dec,

day = "1",

doi = "10.1097/CCM.0000000000005256",

language = "English",

volume = "49",

pages = "e1276--e1277",

journal = "Critical care medicine",

issn = "0090-3493",

publisher = "Lippincott Williams \& Wilkins",

number = "12",

}

TY - JOUR

T1 - Improved Survival Through Early Versus Late Impella Support for Myocardial Infarction-Related Shock?

T2 - Mind Your Step!

AU - Meuwese, Christiaan L

AU - Pladet, Claartje L A

AU - Kraaijeveld, Adriaan O

AU - Donker, Dirk W

N1 - Funding Information: Dr. Kraaijeveld’s institution received funding from Xenios and Abiomed; he received funding from Abiomed. Dr. Donker received funding from Getinge Maquet and Fresenius Xenios Nova Lung. The remaining authors have disclosed that they do not have any potential conflicts of interest.

PY - 2021/12/1

Y1 - 2021/12/1

U2 - 10.1097/CCM.0000000000005256

DO - 10.1097/CCM.0000000000005256

M3 - Comment/Letter to the editor

C2 - 34793400

SN - 0090-3493

VL - 49

SP - e1276-e1277

JO - Critical care medicine

JF - Critical care medicine

IS - 12

ER -